Cancer Immunotherapy: Building on Initial Successes to Improve Clinical Outcomes
Cancer Immunotherapy: Building on Initial Successes to Improve Clinical Outcomes This new report builds on our 2014 Insight Pharma Report, Cancer Immunotherapy: Immune Checkpoint Inhibitors, Cancer Vaccines, and Adoptive T-cell Therapies.
(EMAILWIRE.COM, May 03, 2018 )
MarketIntelReports, Singapore, April 30, 2018.
MarketIntelReports : A global report titled Cancer Immunotherapy Market has been introduced into our library of 2.5 million reports.
Title of the report: Cancer Immunotherapy: Building on Initial Successes to Improve Clinical Outcomes
Year: 2018
Details in the report: This is a 180+ page report with 7 chapters which includes demand analysis by country, application, manufacturers, product categories. Report also includes key developments, market share analysis, market sizing by country, market trends/ future trends, strategic initiatives, key product launches as well.
About the market report:
Cancer Immunotherapy: Building on Initial Successes to Improve Clinical Outcomes
This new report builds on our 2014 Insight Pharma Report, Cancer Immunotherapy: Immune Checkpoint Inhibitors, Cancer Vaccines, and Adoptive T-cell Therapies. In that report, we focused on the major classes of cancer immunotherapy drugs that were then emerging from academic and corporate research: immune checkpoint inhibitors, cancer vaccines, and adoptive T-cell therapies. This new report includes an updated discussion of approved and clinical stage agents in immuno-oncology, including recently-approved agents. It also addresses the means by which researchers and companies are attempting to build on prior achievements in immuno-oncology to improve outcomes for more patients. Some researchers and companies refer to this approach as “immuno-oncology 2.0.” The American Society of Clinical Oncology (ASCO), in its 12th Annual Report on Progress Against Cancer (2017), named “Immunotherapy 2.0” as its “Advance of the Year.”
To access the full table of contents of the report click below: https://www.marketintelreports.com/report/ipr0001/cancer-immunotherapy-building-on-initial-successes-to-improve-clinical-outcomes
Scope of the Report:
This new report includes an updated discussion of approved and clinical stage agents in immuno-oncology, including recently-approved agents. It also addresses the means by which researchers and companies are attempting to build on prior achievements in immuno-oncology to improve outcomes for more patients. Some researchers and companies refer to this approach as “immuno-oncology 2.0.” The American Society of Clinical Oncology (ASCO), in its 12th Annual Report on Progress Against Cancer (2017), named “Immunotherapy 2.0” as its “Advance of the Year.”
There are 7 Chapters to deeply display the Cancer Immunotherapy Market
To find out more of the report or request some customization: https://www.marketintelreports.com/inquiry-before-buying.php?id=ipr0001
Table of Contents-Key Points Covered
EXECUTIVE SUMMARY
Cancer Immunotherapy: Building on Initial Successes to Improve Clinical Outcomes
Approvals of checkpoint inhibitors
Biomarkers for checkpoint inhibitor treatments
Approved and clinical-stage immunotherapy biologics other than checkpoint inhibitors
Immunotherapy with TIL cells
Commercialization of TIL therapy
Adoptive immunotherapy with genetically engineered T cells bearing chimeric antigen receptors (CARs)
Manufacturing issues with CAR T-cell therapies
Adoptive immunotherapy via autologous recombinant TCR technology
General conclusions on the progress of cellular immunotherapy
Outlook for cancer immunotherapy
About Cambridge Healthtech Institute
CHAPTER 1:
Introduction
The early history of cancer immunotherapy – Coley’s toxins
Cytokines as immunomodulatory drugs
Interleukin-2
Alpha-interferons
Interleukin-12
Interleukin-12 as a bridge between innate and adaptive immunity
Investigation of interleukin-12 as an anticancer therapeutic
Interleukin-10
Interleukin-15
Admune/Novartis’ heterodimeric IL-15:IL-15Rα (hetIL-15)
Altor’s ALT-803
Conclusions: Cytokine-based immunotherapies for cancer
CHAPTER 2:
What are immune checkpoints?
CTLA-4 blocking agents
Ipilimumab
Tremelimumab
PD-1 blocking agents
Nivolumab
Combination therapy of nivolumab plus ipilimumab in melanoma
Pembrolizumab
Pembrolizumab as a first-line treatment for advanced NSCLC
Pembrolizumab in colorectal carcinoma with mismatch-repair deficiency
Studies of pembrolizumab in combination immunotherapies
PDR001
PD-L1 blocking agents
Atezolizumab
Atezolizumab in treatment of urothelial carcinoma
Atezolizumab for the treatment of NSCLC
Atezolizumab in treatment of other solid tumors
Other anti-PD-L1 mAb agents
Durvalumab
Avelumab
Anti-LAG-3 agents
anti-TIM-3
NewLink Genetics’ small-molecule IDO pathway inhibitors and checkpoint inhibition
Infinity’s PI3Kγ inhibitor IPI-549 for modulation of immune suppression in tumors
Biomarkers for checkpoint inhibitor treatments
Target biomarkers
Genetic biomarkers
Immunological biomarkers
Use of biomarker tests in treatment with checkpoint inhibitors
Checkpoint inhibitors plus radiation therapy
Checkpoint inhibitors plus targeted therapies
Checkpoint inhibitors with cytotoxic chemotherapies
Discussion
CHAPTER 3:
Continued…..
Complete Report Details @ https://www.marketintelreports.com/report/ipr0001/cancer-immunotherapy-building-on-initial-successes-to-improve-clinical-outcomes
Contact us for any queries on the report:
Lakshmi
Sales Manager
Email : sales@marketintelreports.com
www.marketintelreports.com
Contact Sales: 1-302-261-5343
About us:
MIR intends to be a one-stop shop with an intuitive design, exhaustive database, expert assistance, secure cart checkout and data privacy integrated. It curates the list of reports, publishers and studies to ensure that the database is constantly updated to dynamically meet the targeted, specific needs of our clients.
MarketIntelReports currently has more than 2.5 million titles and 200 publishers on our platform and are growing consistently to fill the “World Intelligence Demand – Supply Gap”. We cover more than 15 industry verticals being: Automotive, Electronics, Manufacturing, Pharmaceuticals, Healthcare, Chemicals, Building & Construction, Agriculture, Food & Beverages, Banking & Finance, Media and Government, Public Sector Studies.
MarketIntelReports, Singapore, April 30, 2018.
MarketIntelReports : A global report titled Cancer Immunotherapy Market has been introduced into our library of 2.5 million reports.
Title of the report: Cancer Immunotherapy: Building on Initial Successes to Improve Clinical Outcomes
Year: 2018
Details in the report: This is a 180+ page report with 7 chapters which includes demand analysis by country, application, manufacturers, product categories. Report also includes key developments, market share analysis, market sizing by country, market trends/ future trends, strategic initiatives, key product launches as well.
About the market report:
Cancer Immunotherapy: Building on Initial Successes to Improve Clinical Outcomes
This new report builds on our 2014 Insight Pharma Report, Cancer Immunotherapy: Immune Checkpoint Inhibitors, Cancer Vaccines, and Adoptive T-cell Therapies. In that report, we focused on the major classes of cancer immunotherapy drugs that were then emerging from academic and corporate research: immune checkpoint inhibitors, cancer vaccines, and adoptive T-cell therapies. This new report includes an updated discussion of approved and clinical stage agents in immuno-oncology, including recently-approved agents. It also addresses the means by which researchers and companies are attempting to build on prior achievements in immuno-oncology to improve outcomes for more patients. Some researchers and companies refer to this approach as “immuno-oncology 2.0.” The American Society of Clinical Oncology (ASCO), in its 12th Annual Report on Progress Against Cancer (2017), named “Immunotherapy 2.0” as its “Advance of the Year.”
To access the full table of contents of the report click below: https://www.marketintelreports.com/report/ipr0001/cancer-immunotherapy-building-on-initial-successes-to-improve-clinical-outcomes
Scope of the Report:
This new report includes an updated discussion of approved and clinical stage agents in immuno-oncology, including recently-approved agents. It also addresses the means by which researchers and companies are attempting to build on prior achievements in immuno-oncology to improve outcomes for more patients. Some researchers and companies refer to this approach as “immuno-oncology 2.0.” The American Society of Clinical Oncology (ASCO), in its 12th Annual Report on Progress Against Cancer (2017), named “Immunotherapy 2.0” as its “Advance of the Year.”
There are 7 Chapters to deeply display the Cancer Immunotherapy Market
To find out more of the report or request some customization: https://www.marketintelreports.com/inquiry-before-buying.php?id=ipr0001
Table of Contents-Key Points Covered
EXECUTIVE SUMMARY
Cancer Immunotherapy: Building on Initial Successes to Improve Clinical Outcomes
Approvals of checkpoint inhibitors
Biomarkers for checkpoint inhibitor treatments
Approved and clinical-stage immunotherapy biologics other than checkpoint inhibitors
Immunotherapy with TIL cells
Commercialization of TIL therapy
Adoptive immunotherapy with genetically engineered T cells bearing chimeric antigen receptors (CARs)
Manufacturing issues with CAR T-cell therapies
Adoptive immunotherapy via autologous recombinant TCR technology
General conclusions on the progress of cellular immunotherapy
Outlook for cancer immunotherapy
About Cambridge Healthtech Institute
CHAPTER 1:
Introduction
The early history of cancer immunotherapy – Coley’s toxins
Cytokines as immunomodulatory drugs
Interleukin-2
Alpha-interferons
Interleukin-12
Interleukin-12 as a bridge between innate and adaptive immunity
Investigation of interleukin-12 as an anticancer therapeutic
Interleukin-10
Interleukin-15
Admune/Novartis’ heterodimeric IL-15:IL-15Rα (hetIL-15)
Altor’s ALT-803
Conclusions: Cytokine-based immunotherapies for cancer
CHAPTER 2:
What are immune checkpoints?
CTLA-4 blocking agents
Ipilimumab
Tremelimumab
PD-1 blocking agents
Nivolumab
Combination therapy of nivolumab plus ipilimumab in melanoma
Pembrolizumab
Pembrolizumab as a first-line treatment for advanced NSCLC
Pembrolizumab in colorectal carcinoma with mismatch-repair deficiency
Studies of pembrolizumab in combination immunotherapies
PDR001
PD-L1 blocking agents
Atezolizumab
Atezolizumab in treatment of urothelial carcinoma
Atezolizumab for the treatment of NSCLC
Atezolizumab in treatment of other solid tumors
Other anti-PD-L1 mAb agents
Durvalumab
Avelumab
Anti-LAG-3 agents
anti-TIM-3
NewLink Genetics’ small-molecule IDO pathway inhibitors and checkpoint inhibition
Infinity’s PI3Kγ inhibitor IPI-549 for modulation of immune suppression in tumors
Biomarkers for checkpoint inhibitor treatments
Target biomarkers
Genetic biomarkers
Immunological biomarkers
Use of biomarker tests in treatment with checkpoint inhibitors
Checkpoint inhibitors plus radiation therapy
Checkpoint inhibitors plus targeted therapies
Checkpoint inhibitors with cytotoxic chemotherapies
Discussion
CHAPTER 3:
Continued…..
Complete Report Details @ https://www.marketintelreports.com/report/ipr0001/cancer-immunotherapy-building-on-initial-successes-to-improve-clinical-outcomes
Contact us for any queries on the report:
Lakshmi
Sales Manager
Email : sales@marketintelreports.com
www.marketintelreports.com
Contact Sales: 1-302-261-5343
About us:
MIR intends to be a one-stop shop with an intuitive design, exhaustive database, expert assistance, secure cart checkout and data privacy integrated. It curates the list of reports, publishers and studies to ensure that the database is constantly updated to dynamically meet the targeted, specific needs of our clients.
MarketIntelReports currently has more than 2.5 million titles and 200 publishers on our platform and are growing consistently to fill the “World Intelligence Demand – Supply Gap”. We cover more than 15 industry verticals being: Automotive, Electronics, Manufacturing, Pharmaceuticals, Healthcare, Chemicals, Building & Construction, Agriculture, Food & Beverages, Banking & Finance, Media and Government, Public Sector Studies.
Contact Information:
MarketIntelReports
Venkat
Tel: 1-302-261-5343
Email us
----
This press release is posted on EmailWire.com -- a global newswire that provides Press Release Distribution Services with Guaranteed Results
MarketIntelReports
Venkat
Tel: 1-302-261-5343
Email us
----
This press release is posted on EmailWire.com -- a global newswire that provides Press Release Distribution Services with Guaranteed Results